ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2023
Quality of life should be the primary outcome for disease modifying therapy trials in MS-No.
Emm Strijbis et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this paperpooled itcites it